Search Result

Results for "

hepatic PCSK9

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PCSK9 (3) Small Interfering RNA (siRNA) (1)
By Research Areas:	Cardiovascular Disease (1) Inflammation/Immunology (2) Metabolic Disease (2)
Oligonucleotides:	siRNA drugs (1) siRNAs (1)

Inhibitors & Agonists

Peptides

Oligonucleotides

Targets Recommended: PCSK9

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150223

GalNAc unconjugated/naked Inclisiran 1 Publications Verification	PCSK9 Small Interfering RNA (siRNA)	Cardiovascular Disease
GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA molecule that targets hepatic *PCSK9* production to reduce LDL-C levels. GalNAc unconjugated/naked Inclisiran can be used in the research of cardiovascular diseases and hypercholesterolemia .

HY-162562

E28362	PCSK9	Metabolic Disease Inflammation/Immunology
E28362 is an orally active lipid-lowering agent and a selective *PCSK9* antagonist. E28362 blocks the interaction between *PCSK9* and LDLR, and induces PCSK9 degradation via the ubiquitin-proteasome pathway. E28362 significantly increases the levels of cell surface and total LDLR proteins, enhances low-density lipoprotein uptake, thereby effectively reducing plasma lipids, hepatic cholesterol and triglyceride levels. E28362 shows no obvious cytotoxicity at high concentrations, and significantly attenuates atherosclerotic lesions in animal models. E28362 is an important molecule in research of hyperlipidemia and atherosclerosis .

HY-W1126955

Enlicitide (decanoate) MK-0616 (decanoate)	PCSK9	Metabolic Disease Inflammation/Immunology
Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide *PCSK9* inhibitor. Enlicitide decanoate binds to *PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR), and enhances hepatic* clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease .

Cat. No.	Product Name	Target	Research Area

HY-W1126955

Enlicitide (decanoate) MK-0616 (decanoate)	PCSK9	Metabolic Disease Inflammation/Immunology
Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide *PCSK9* inhibitor. Enlicitide decanoate binds to *PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR), and enhances hepatic* clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease .

Cat. No.	Product Name		Classification

HY-150223

GalNAc unconjugated/naked Inclisiran 1 Publications Verification		siRNAs siRNA drugs
GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA molecule that targets hepatic *PCSK9* production to reduce LDL-C levels. GalNAc unconjugated/naked Inclisiran can be used in the research of cardiovascular diseases and hypercholesterolemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.